IP Library › Granted Patent US 12,496,470
Granted Patent B2
US 12,496,470 · App. 17/863,864 · Granted Dec 16, 2025

Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments

Inventors: Alina Baum (Pleasantville, NY); Christos Kyratsous (Irvington, NY); George D. Yancopoulos (Yorktown Heights, NY)
Assignee: Regeneron Pharmaceuticals, Inc.
A61K39/42A61P31/14C07K14/005C07K16/1003C12N15/85A61K2039/505C07K2317/21C07K2317/31C07K2317/33C07K2317/565C07K2317/732C07K2317/76C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,496,470
App. No.
17/863,864
Granted
Dec 16, 2025
Kind
B2
Abstract

The present disclosure provides antibodies and antigen-binding fragments thereof that bind specifically to a coronavirus spike protein and methods of using such antibodies and fragments for treating or preventing viral infections (e.g., coronavirus infections).

Claims (149)

1 . An isolated recombinant antibody or antigen-binding fragment thereof that specifically binds to a coronavirus spike protein (CoV-S), wherein the antibody or antigen-binding fragment comprises:

a heavy chain variable region (HCVR) comprising three heavy chain complementarity determining regions (CDRs) (HCDR1, HCDR2, and HCDR3); and a light chain variable region (LCVR) comprising three light chain CDRs (LCDR1, LCDR2, and LCDR3);

wherein the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3, comprise, respectively, the amino acid sequences of:

SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 12, EVS, and SEQ ID NO: 16;

SEQ ID NO: 24, SEQ ID NO: 26, SEQ ID NO: 28, SEQ ID NO: 32, EGN, and SEQ ID NO: 36;

SEQ ID NO: 44, SEQ ID NO: 26, SEQ ID NO: 47, SEQ ID NO: 51, EGN, and SEQ ID NO: 36;

SEQ ID NO: 60, SEQ ID NO: 62, SEQ ID NO: 64, SEQ ID NO: 51, EGT, and SEQ ID NO: 36;

SEQ ID NO: 76, SEQ ID NO: 78, SEQ ID NO: 80, SEQ ID NO: 84, EDS, and SEQ ID NO: 88;

SEQ ID NO: 96, SEQ ID NO: 98, SEQ ID NO: 100, SEQ ID NO: 104, AAS, and SEQ ID NO: 108;

SEQ ID NO: 116, SEQ ID NO: 118, SEQ ID NO: 120, SEQ ID NO: 124, GAS, and SEQ ID NO: 128;

SEQ ID NO: 136, SEQ ID NO: 138, SEQ ID NO: 140, SEQ ID NO: 144, GAS, and SEQ ID NO: 146;

SEQ ID NO: 154, SEQ ID NO: 156, SEQ ID NO: 158, SEQ ID NO: 162, GNS, and SEQ ID NO: 166;

SEQ ID NO: 174, SEQ ID NO: 176, SEQ ID NO: 178, SEQ ID NO: 182, SND, and SEQ ID NO: 186;

SEQ ID NO: 194, SEQ ID NO: 196, SEQ ID NO: 198, SEQ ID NO: 202, DND, and SEQ ID NO: 206;

SEQ ID NO: 214, SEQ ID NO: 216, SEQ ID NO: 218, SEQ ID NO: 222, GAS, and SEQ ID NO: 224;

SEQ ID NO: 232, SEQ ID NO: 234, SEQ ID NO: 236, SEQ ID NO: 240, DAS, and SEQ ID NO: 244;

SEQ ID NO: 252, SEQ ID NO: 254, SEQ ID NO: 256, SEQ ID NO: 260, GAT, and SEQ ID NO: 264;

SEQ ID NO: 272, SEQ ID NO: 274, SEQ ID NO: 276, SEQ ID NO: 280, AAS, and SEQ ID NO: 282;

SEQ ID NO: 290, SEQ ID NO: 292, SEQ ID NO: 294, SEQ ID NO: 298, SDN, and SEQ ID NO: 302;

SEQ ID NO: 310, SEQ ID NO: 312, SEQ ID NO: 314, SEQ ID NO: 318, VNN, and SEQ ID NO: 322;

SEQ ID NO: 330, SEQ ID NO: 332, SEQ ID NO: 334, SEQ ID NO: 338, AAS, and SEQ ID NO: 340;

SEQ ID NO: 96, SEQ ID NO: 98, SEQ ID NO: 350, SEQ ID NO: 354, AAS, and SEQ ID NO: 356;

SEQ ID NO: 364, SEQ ID NO: 366, SEQ ID NO: 368, SEQ ID NO: 372, AAS, and SEQ ID NO: 374;

SEQ ID NO: 382, SEQ ID NO: 384, SEQ ID NO: 386, SEQ ID NO: 390, KAS, and SEQ ID NO: 394;

SEQ ID NO: 402, SEQ ID NO: 98, SEQ ID NO: 405, SEQ ID NO: 409, DAS, and SEQ ID NO: 411;

SEQ ID NO: 419, SEQ ID NO: 421, SEQ ID NO: 423, SEQ ID NO: 427, EVS, and SEQ ID NO: 429;

SEQ ID NO: 437, SEQ ID NO: 138, SEQ ID NO: 440, SEQ ID NO: 444, DKN, and SEQ ID NO: 448;

SEQ ID NO: 456, SEQ ID NO: 458, SEQ ID NO: 460, SEQ ID NO: 84, ELT, and SEQ ID NO: 467;

SEQ ID NO: 475, SEQ ID NO: 477, SEQ ID NO: 479, SEQ ID NO: 483, DVT, and SEQ ID NO: 487;

SEQ ID NO: 495, SEQ ID NO: 497, SEQ ID NO: 499, SEQ ID NO: 503, EVT, and SEQ ID NO: 507;

SEQ ID NO: 515, SEQ ID NO: 517, SEQ ID NO: 519, SEQ ID NO: 523, EGS, and SEQ ID NO: 36;

SEQ ID NO: 533, SEQ ID NO: 535, SEQ ID NO: 537, SEQ ID NO: 483, DVS, and SEQ ID NO: 544;

SEQ ID NO: 552, SEQ ID NO: 554, SEQ ID NO: 556, SEQ ID NO: 84, EVS, and SEQ ID NO: 560;

SEQ ID NO: 568, SEQ ID NO: 570, SEQ ID NO: 572, SEQ ID NO: 576, ENN, and SEQ ID NO: 580;

SEQ ID NO: 588, SEQ ID NO: 590, SEQ ID NO: 592, SEQ ID NO: 596, GAS, and SEQ ID NO: 598;

SEQ ID NO: 606, SEQ ID NO: 608, SEQ ID NO: 610, SEQ ID NO: 614, GAS, and SEQ ID NO: 616;

SEQ ID NO: 624, SEQ ID NO: 626, SEQ ID NO: 628, SEQ ID NO: 632, LGS, and SEQ ID NO: 636;

SEQ ID NO: 644, SEQ ID NO: 646, SEQ ID NO: 648, SEQ ID NO: 652, LGS, and SEQ ID NO: 655;

SEQ ID NO: 663, SEQ ID NO: 665, SEQ ID NO: 667, SEQ ID NO: 124, GAS, and SEQ ID NO: 671;

SEQ ID NO: 679, SEQ ID NO: 78, SEQ ID NO: 682, SEQ ID NO: 686, GAS, and SEQ ID NO: 688;

SEQ ID NO: 696, SEQ ID NO: 698, SEQ ID NO: 700, SEQ ID NO: 704, SAS, and SEQ ID NO: 708;

SEQ ID NO: 696, SEQ ID NO: 716, SEQ ID NO: 718, SEQ ID NO: 722, GAS, and SEQ ID NO: 724;

SEQ ID NO: 732, SEQ ID NO: 734, SEQ ID NO: 736, SEQ ID NO: 740, AAS, and SEQ ID NO: 742;

SEQ ID NO: 750, SEQ ID NO: 497, SEQ ID NO: 752, SEQ ID NO: 756, EVT, and SEQ ID NO: 758;

SEQ ID NO: 766, SEQ ID NO: 768, SEQ ID NO: 770, SEQ ID NO: 774, KDS, and SEQ ID NO: 778;

SEQ ID NO: 786, SEQ ID NO: 788, SEQ ID NO: 790, SEQ ID NO: 794, GNT, and SEQ ID NO: 798;

SEQ ID NO: 806, SEQ ID NO: 497, SEQ ID NO: 808, SEQ ID NO: 812, EVT, and SEQ ID NO: 814;

SEQ ID NO: 822, SEQ ID NO: 497, SEQ ID NO: 825, SEQ ID NO: 756, EVS, and SEQ ID NO: 829;

SEQ ID NO: 837, SEQ ID NO: 839, SEQ ID NO: 841, SEQ ID NO: 845, KIS, and SEQ ID NO: 849;

SEQ ID NO: 857, SEQ ID NO: 859, SEQ ID NO: 861, SEQ ID NO: 865, AAS, and SEQ ID NO: 867;

SEQ ID NO: 76, SEQ ID NO: 876, SEQ ID NO: 878, SEQ ID NO: 84, EDS, and SEQ ID NO: 36;

SEQ ID NO: 889, SEQ ID NO: 891, SEQ ID NO: 893, SEQ ID NO: 897, GNS, and SEQ ID NO: 899;

SEQ ID NO: 154, SEQ ID NO: 908, SEQ ID NO: 910, SEQ ID NO: 914, GHT, and SEQ ID NO: 166;

SEQ ID NO: 924, SEQ ID NO: 926, SEQ ID NO: 928, SEQ ID NO: 576, RNN, and SEQ ID NO: 935;

SEQ ID NO: 943, SEQ ID NO: 945, SEQ ID NO: 947, SEQ ID NO: 951, LGS, and SEQ ID NO: 655;

SEQ ID NO: 959, SEQ ID NO: 961, SEQ ID NO: 963, SEQ ID NO: 967, WAS, and SEQ ID NO: 971;

SEQ ID NO: 696, SEQ ID NO: 698, SEQ ID NO: 700, SEQ ID NO: 704, SAS, and SEQ ID NO: 979;

SEQ ID NO: 696, SEQ ID NO: 698, SEQ ID NO: 700, SEQ ID NO: 704, SAS, and SEQ ID NO: 985; or

SEQ ID NO: 991, SEQ ID NO: 993, SEQ ID NO: 995, SEQ ID NO: 999, GAS, and SEQ ID NO: 1003.

2 . The antibody or antigen-binding fragment of claim 1 , wherein the antibody or antigen-binding fragment has one or more of the following characteristics:

(a) binds to CoV-S with an EC 50 of less than about 10 −8 M; and/or

(b) demonstrates an increase in survival in a coronavirus-infected animal after administration to said coronavirus-infected animal, as compared to a comparable coronavirus-infected animal without said administration.

3 . The antibody or antigen-binding fragment of claim 1 , wherein the HCVR and the LCVR comprise, respectively, the amino acid sequences selected from the group consisting of SEQ ID NOs: 2 and 10; 22 and 30; 42 and 49; 58 and 66; 74 and 82; 94 and 102; 114 and 122; 134 and 142; 152 and 160; 172 and 180; 192 and 200; 212 and 220; 230 and 238; 250 and 258; 270 and 278; 288 and 296; 308 and 316; 328 and 336; 346 and 352; 362 and 370; 380 and 388; 400 and 407; 417 and 425; 435 and 442; 454 and 462; 473 and 481; 493 and 501; 513 and 521; 531 and 539; 550 and 558; 566 and 574; 586 and 594; 604 and 612; 622 and 630; 642 and 650; 661 and 669; 677 and 684; 694 and 702; 714 and 720; 730 and 738; 748 and 754; 764 and 772; 784 and 792; 804 and 810; 820 and 827; 835 and 843; 855 and 863; 873 and 880; 887 and 895; 905 and 912; 922 and 930; 941 and 949; 957 and 965; 694 and 977; 694 and 983; and 989 and 997.

4 . The antibody or antigen-binding fragment of claim 1 , which is an antibody comprising a heavy chain and a light chain, wherein the heavy chain (HC) and the light chain (LC) comprise, respectively, the amino acid sequences selected from the group consisting of SEQ ID NOs: 18 and 20; 38 and 40; 54 and 56; 70 and 72; 90 and 92; 110 and 112; 130 and 132; 148 and 150; 168 and 170; 188 and 190; 208 and 210; 226 and 228; 246 and 248; 266 and 268; 284 and 286; 304 and 306; 324 and 326; 342 and 344; 358 and 360; 376 and 378; 396 and 398; 413 and 415; 431 and 433; 450 and 452; 469 and 471; 489 and 491; 509 and 511; 527 and 529; 546 and 548; 562 and 564; 582 and 584; 600 and 602; 618 and 620; 638 and 640; 657 and 659; 673 and 675; 690 and 692; 710 and 712; 726 and 728; 744 and 746; 760 and 762; 780 and 782; 800 and 802; 816 and 818; 831 and 833; 851 and 853; 869 and 871; 883 and 885; 901 and 903; 918 and 920; 937 and 939; 953 and 955; 973 and 975; 710 and 981; 710 and 987; 1005 and 1007; 1075 and 511; and 1077 and 378.

5 . An antibody or antigen-binding fragment thereof that competes with the antibody or antigen-binding fragment of claim 1 for binding to CoV-S, or that binds to the same epitope as, or to an overlapping epitope on, CoV-S as the antibody or antigen-binding fragment of claim 1 .

6 . The antibody or antigen-binding fragment of claim 1 , which:

(i) is multispecific;

(ii) comprises one or more of the following properties:

(a) inhibits growth of coronavirus;

(b) binds to the surface of a coronavirus;

(c) limits spread of coronavirus infection of cells in vitro; and

(d) protects mice engineered to express the human ACE2 or TMPRSS2 protein from death and/or weight loss caused by coronavirus infection; and/or

(iii) is an antibody or antigen-binding fragment wherein said CoV-S is SARS-COV-2-S.

7 . A polynucleotide encoding:

(a) an antibody or antigen-binding fragment thereof of claim 1 ;

(b) a HCVR and a LCVR comprising the HCVR and LCVR sequences, respectively, selected from the group consisting of SEQ ID NOs: 2 and 10; 22 and 30; 42 and 49; 58 and 66; 74 and 82; 94 and 102; 114 and 122; 134 and 142; 152 and 160; 172 and 180; 192 and 200; 212 and 220; 230 and 238; 250 and 258; 270 and 278; 288 and 296; 308 and 316; 328 and 336; 346 and 352; 362 and 370; 380 and 388; 400 and 407; 417 and 425; 435 and 442; 454 and 462; 473 and 481; 493 and 501; 513 and 521; 531 and 539; 550 and 558; 566 and 574; 586 and 594; 604 and 612; 622 and 630; 642 and 650; 661 and 669; 677 and 684; 694 and 702; 714 and 720; 730 and 738; 748 and 754; 764 and 772; 784 and 792; 804 and 810; 820 and 827; 835 and 843; 855 and 863; 873 and 880; 887 and 895; 905 and 912; 922 and 930; 941 and 949; 957 and 965; 694 and 977; 694 and 983; and 989 and 997; or

(c) a heavy chain (HC) and a light chain (LC) comprising the HC and LC sequences, respectively, selected from the group consisting of SEQ ID NOs: 18 and 20; 38 and 40; 54 and 56; 70 and 72; 90 and 92; 110 and 112; 130 and 132; 148 and 150; 168 and 170; 188 and 190; 208 and 210; 226 and 228; 246 and 248; 266 and 268; 284 and 286; 304 and 306; 324 and 326; 342 and 344; 358 and 360; 376 and 378; 396 and 398; 413 and 415; 431 and 433; 450 and 452; 469 and 471; 489 and 491; 509 and 511; 527 and 529; 546 and 548; 562 and 564; 582 and 584; 600 and 602; 618 and 620; 638 and 640; 657 and 659; 673 and 675; 690 and 692; 710 and 712; 726 and 728; 744 and 746; 760 and 762; 780 and 782; 800 and 802; 816 and 818; 831 and 833; 851 and 853; 869 and 871; 883 and 885; 901 and 903; 918 and 920; 937 and 939; 953 and 955; 973 and 975; 710 and 981; 710 and 987; 1005 and 1007; 1075 and 511; and 1077 and 378.

8 . A vector comprising the polynucleotide of claim 7 .

9 . An isolated host cell comprising the antibody or antigen-binding fragment of claim 1 .

10 . A pair of polynucleotides, wherein:

(a) the first polynucleotide encodes a heavy chain variable region (HCVR) comprising three heavy chain complementarity determining regions (CDRs) (HCDR1, HCDR2, and HCDR3), and the second polynucleotide encodes a light chain variable region (LCVR) comprising three light chain CDRs (LCDR1, LCDR2, and LCDR3), wherein the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3, comprise, respectively, the amino acid sequences of:

SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 12, EVS, and SEQ ID NO: 16;

SEQ ID NO: 24, SEQ ID NO: 26, SEQ ID NO: 28, SEQ ID NO: 32, EGN, and SEQ ID NO: 36;

SEQ ID NO: 44, SEQ ID NO: 26, SEQ ID NO: 47, SEQ ID NO: 51, EGN, and SEQ ID NO: 36;

SEQ ID NO: 60, SEQ ID NO: 62, SEQ ID NO: 64, SEQ ID NO: 51, EGT, and SEQ ID NO: 36;

SEQ ID NO: 76, SEQ ID NO: 78, SEQ ID NO: 80, SEQ ID NO: 84, EDS, and SEQ ID NO: 88;

SEQ ID NO: 96, SEQ ID NO: 98, SEQ ID NO: 100, SEQ ID NO: 104, AAS, and SEQ ID NO: 108;

SEQ ID NO: 116, SEQ ID NO: 118, SEQ ID NO: 120, SEQ ID NO: 124, GAS, and SEQ ID NO: 128;

SEQ ID NO: 136, SEQ ID NO: 138, SEQ ID NO: 140, SEQ ID NO: 144, GAS, and SEQ ID NO: 146;

SEQ ID NO: 154, SEQ ID NO: 156, SEQ ID NO: 158, SEQ ID NO: 162, GNS, and SEQ ID NO: 166;

SEQ ID NO: 174, SEQ ID NO: 176, SEQ ID NO: 178, SEQ ID NO: 182, SND, and SEQ ID NO: 186;

SEQ ID NO: 194, SEQ ID NO: 196, SEQ ID NO: 198, SEQ ID NO: 202, DND, and SEQ ID NO: 206;

SEQ ID NO: 214, SEQ ID NO: 216, SEQ ID NO: 218, SEQ ID NO: 222, GAS, and SEQ ID NO: 224;

SEQ ID NO: 232, SEQ ID NO: 234, SEQ ID NO: 236, SEQ ID NO: 240, DAS, and SEQ ID NO: 244;

SEQ ID NO: 252, SEQ ID NO: 254, SEQ ID NO: 256, SEQ ID NO: 260, GAT, and SEQ ID NO: 264;

SEQ ID NO: 272, SEQ ID NO: 274, SEQ ID NO: 276, SEQ ID NO: 280, AAS, and SEQ ID NO: 282;

SEQ ID NO: 290, SEQ ID NO: 292, SEQ ID NO: 294, SEQ ID NO: 298, SDN, and SEQ ID NO: 302;

SEQ ID NO: 310, SEQ ID NO: 312, SEQ ID NO: 314, SEQ ID NO: 318, VNN, and SEQ ID NO: 322;

SEQ ID NO: 330, SEQ ID NO: 332, SEQ ID NO: 334, SEQ ID NO: 338, AAS, and SEQ ID NO: 340;

SEQ ID NO: 96, SEQ ID NO: 98, SEQ ID NO: 350, SEQ ID NO: 354, AAS, and SEQ ID NO: 356;

SEQ ID NO: 364, SEQ ID NO: 366, SEQ ID NO: 368, SEQ ID NO: 372, AAS, and SEQ ID NO: 374;

SEQ ID NO: 382, SEQ ID NO: 384, SEQ ID NO: 386, SEQ ID NO: 390, KAS, and SEQ ID NO: 394;

SEQ ID NO: 402, SEQ ID NO: 98, SEQ ID NO: 405, SEQ ID NO: 409, DAS, and SEQ ID NO: 411;

SEQ ID NO: 419, SEQ ID NO: 421, SEQ ID NO: 423, SEQ ID NO: 427, EVS, and SEQ ID NO: 429;

SEQ ID NO: 437, SEQ ID NO: 138, SEQ ID NO: 440, SEQ ID NO: 444, DKN, and SEQ ID NO: 448;

SEQ ID NO: 456, SEQ ID NO: 458, SEQ ID NO: 460, SEQ ID NO: 84, ELT, and SEQ ID NO: 467;

SEQ ID NO: 475, SEQ ID NO: 477, SEQ ID NO: 479, SEQ ID NO: 483, DVT, and SEQ ID NO: 487;

SEQ ID NO: 495, SEQ ID NO: 497, SEQ ID NO: 499, SEQ ID NO: 503, EVT, and SEQ ID NO: 507;

SEQ ID NO: 515, SEQ ID NO: 517, SEQ ID NO: 519, SEQ ID NO: 523, EGS, and SEQ ID NO: 36;

SEQ ID NO: 533, SEQ ID NO: 535, SEQ ID NO: 537, SEQ ID NO: 483, DVS, and SEQ ID NO: 544;

SEQ ID NO: 552, SEQ ID NO: 554, SEQ ID NO: 556, SEQ ID NO: 84, EVS, and SEQ ID NO: 560;

SEQ ID NO: 568, SEQ ID NO: 570, SEQ ID NO: 572, SEQ ID NO: 576, ENN, and SEQ ID NO: 580;

SEQ ID NO: 588, SEQ ID NO: 590, SEQ ID NO: 592, SEQ ID NO: 596, GAS, and SEQ ID NO: 598;

SEQ ID NO: 606, SEQ ID NO: 608, SEQ ID NO: 610, SEQ ID NO: 614, GAS, and SEQ ID NO: 616;

SEQ ID NO: 624, SEQ ID NO: 626, SEQ ID NO: 628, SEQ ID NO: 632, LGS, and SEQ ID NO: 636;

SEQ ID NO: 644, SEQ ID NO: 646, SEQ ID NO: 648, SEQ ID NO: 652, LGS, and SEQ ID NO: 655;

SEQ ID NO: 663, SEQ ID NO: 665, SEQ ID NO: 667, SEQ ID NO: 124, GAS, and SEQ ID NO: 671;

SEQ ID NO: 679, SEQ ID NO: 78, SEQ ID NO: 682, SEQ ID NO: 686, GAS, and SEQ ID NO: 688;

SEQ ID NO: 696, SEQ ID NO: 698, SEQ ID NO: 700, SEQ ID NO: 704, SAS, and SEQ ID NO: 708;

SEQ ID NO: 696, SEQ ID NO: 716, SEQ ID NO: 718, SEQ ID NO: 722, GAS, and SEQ ID NO: 724;

SEQ ID NO: 732, SEQ ID NO: 734, SEQ ID NO: 736, SEQ ID NO: 740, AAS, and SEQ ID NO: 742;

SEQ ID NO: 750, SEQ ID NO: 497, SEQ ID NO: 752, SEQ ID NO: 756, EVT, and SEQ ID NO: 758;

SEQ ID NO: 766, SEQ ID NO: 768, SEQ ID NO: 770, SEQ ID NO: 774, KDS, and SEQ ID NO: 778;

SEQ ID NO: 786, SEQ ID NO: 788, SEQ ID NO: 790, SEQ ID NO: 794, GNT, and SEQ ID NO: 798;

SEQ ID NO: 806, SEQ ID NO: 497, SEQ ID NO: 808, SEQ ID NO: 812, EVT, and SEQ ID NO: 814;

SEQ ID NO: 822, SEQ ID NO: 497, SEQ ID NO: 825, SEQ ID NO: 756, EVS, and SEQ ID NO: 829;

SEQ ID NO: 837, SEQ ID NO: 839, SEQ ID NO: 841, SEQ ID NO: 845, KIS, and SEQ ID NO: 849;

SEQ ID NO: 857, SEQ ID NO: 859, SEQ ID NO: 861, SEQ ID NO: 865, AAS, and SEQ ID NO: 867;

SEQ ID NO: 76, SEQ ID NO: 876, SEQ ID NO: 878, SEQ ID NO: 84, EDS, and SEQ ID NO: 36;

SEQ ID NO: 889, SEQ ID NO: 891, SEQ ID NO: 893, SEQ ID NO: 897, GNS, and SEQ ID NO: 899;

SEQ ID NO: 154, SEQ ID NO: 908, SEQ ID NO: 910, SEQ ID NO: 914, GHT, and SEQ ID NO: 166;

SEQ ID NO: 924, SEQ ID NO: 926, SEQ ID NO: 928, SEQ ID NO: 576, RNN, and SEQ ID NO: 935;

SEQ ID NO: 943, SEQ ID NO: 945, SEQ ID NO: 947, SEQ ID NO: 951, LGS, and SEQ ID NO: 655;

SEQ ID NO: 959, SEQ ID NO: 961, SEQ ID NO: 963, SEQ ID NO: 967, WAS, and SEQ ID NO: 971;

SEQ ID NO: 696, SEQ ID NO: 698, SEQ ID NO: 700, SEQ ID NO: 704, SAS, and SEQ ID NO: 979;

SEQ ID NO: 696, SEQ ID NO: 698, SEQ ID NO: 700, SEQ ID NO: 704, SAS, and SEQ ID NO: 985; or

SEQ ID NO: 991, SEQ ID NO: 993, SEQ ID NO: 995, SEQ ID NO: 999, GAS, and SEQ ID NO: 1003;

(b) the first polynucleotide encodes a HCVR, and the second polynucleotide encodes a LCVR, wherein the HCVR and the LCVR comprise, respectively, the amino acid sequences of SEQ ID NOs: 2 and 10; 22 and 30; 42 and 49; 58 and 66; 74 and 82; 94 and 102; 114 and 122; 134 and 142; 152 and 160; 172 and 180; 192 and 200; 212 and 220; 230 and 238; 250 and 258; 270 and 278; 288 and 296; 308 and 316; 328 and 336; 346 and 352; 362 and 370; 380 and 388; 400 and 407; 417 and 425; 435 and 442; 454 and 462; 473 and 481; 493 and 501; 513 and 521; 531 and 539; 550 and 558; 566 and 574; 586 and 594; 604 and 612; 622 and 630; 642 and 650; 661 and 669; 677 and 684; 694 and 702; 714 and 720; 730 and 738; 748 and 754; 764 and 772; 784 and 792; 804 and 810; 820 and 827; 835 and 843; 855 and 863; 873 and 880; 887 and 895; 905 and 912; 922 and 930; 941 and 949; 957 and 965; 694 and 977; 694 and 983; or 989 and 997; or

(c) the first polynucleotide a heavy chain, and the second polynucleotide encodes a light chain, wherein the heavy chain and the light chain comprise, respectively, the amino acid sequences of SEQ ID NOs: 18 and 20; 38 and 40; 54 and 56; 70 and 72; 90 and 92; 110 and 112; 130 and 132; 148 and 150; 168 and 170; 188 and 190; 208 and 210; 226 and 228; 246 and 248; 266 and 268; 284 and 286; 304 and 306; 324 and 326; 342 and 344; 358 and 360; 376 and 378; 396 and 398; 413 and 415; 431 and 433; 450 and 452; 469 and 471; 489 and 491; 509 and 511; 527 and 529; 546 and 548; 562 and 564; 582 and 584; 600 and 602; 618 and 620; 638 and 640; 657 and 659; 673 and 675; 690 and 692; 710 and 712; 726 and 728; 744 and 746; 760 and 762; 780 and 782; 800 and 802; 816 and 818; 831 and 833; 851 and 853; 869 and 871; 883 and 885; 901 and 903; 918 and 920; 937 and 939; 953 and 955; 973 and 975; 710 and 981; 710 and 987; 1005 and 1007; 1075 and 511; or 1077 and 378.

11 . A composition or kit comprising the antibody or antigen-binding fragment of claim 1 and a further therapeutic agent, or a pharmaceutical composition comprising the antibody or antigen-binding fragment of claim 1 and pharmaceutically acceptable carrier and, optionally, a further therapeutic agent.

12 . A vessel or injection device comprising the antibody or antigen-binding fragment of claim 1 .

13 . The antibody or antigen-binding fragment thereof of claim 1 that (a) neutralizes an omicron variant of SARS-COV-2, or (b) neutralizes an omicron variant selected from BA.1, BA.1.1, BA.2, BA.2.12.1, BA.3, or BA.4/BA.5.

14 . The antibody or antigen-binding fragment of claim 1 comprising a heavy chain constant region with 252Y, 254T and 256E modifications.

15 . A pair of vectors comprising, respectively, the first polynucleotide and the second polynucleotide of claim 10 .

16 . An isolated host cell comprising the pair of polynucleotides of claim 10 .

17 . An isolated host cell comprising the pair of vectors of claim 15 .

18 . An isolated host cell comprising the polynucleotide of claim 7 .

19 . An isolated host cell comprising the vector of claim 8 .

20 . An isolated host cell comprising the antibody or antigen-binding fragment of claim 3 .

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 5, 2023
From: BAUM, ALINA; KYRATSOUS, CHRISTOS; YANCOPOULOS, GEORGE D.
To: REGENERON PHARMACEUTICALS, INC.
Reel/Frame 065769/0960 →
Continuity (10)
Provisional Application 63354632 · Jun 22, 2022
Provisional Application 63306909 · Feb 4, 2022
Provisional Application 63301002 · Jan 19, 2022
Provisional Application 63291328 · Dec 17, 2021
Provisional Application 63289419 · Dec 14, 2021
Provisional Application 63289126 · Dec 13, 2021
Provisional Application 63286514 · Dec 6, 2021
Provisional Application 63245020 · Sep 16, 2021
Provisional Application 63221846 · Jul 14, 2021
Related Publication 20230125469A1 · Apr 27, 2023
References Cited (400)
US 5908635A · Thierry · 1999 [cited by applicant]
US 10787501B1 · Babb et al. · 2020 [cited by applicant]
US 10822379B1 · Dimitrov et al. · 2020 [cited by applicant]
US 10954289B1 · Babb et al. · 2021 [cited by applicant]
US 10975139B1 · Babb et al. · 2021 [cited by applicant]
US 11020474B1 · Xiang et al. · 2021 [cited by applicant]
US 11021531B1 · Glanville et al. · 2021 [cited by applicant]
US 11021532B1 · Glanville et al. · 2021 [cited by applicant]
US 11028150B1 · Glanville et al. · 2021 [cited by applicant]
US 11028167B1 · Glanville et al. · 2021 [cited by applicant]
US 11732030B2 · Babb et al. · 2023 [cited by applicant]
US 11999777B2 · Ganguly et al. · 2024 [cited by applicant]
US 20060240551A1 · Jiang et al. · 2006 [cited by applicant]
US 20110159001A1 · Lanzavecchia · 2011 [cited by applicant]
US 20170096455A1 · Baric et al. · 2017 [cited by applicant]
US 20170355756A1 · Julien · 2017 [cited by examiner]
US 20210031123A1 · Liu et al. · 2021 [cited by applicant]
US 20210093709A1 · Wu et al. · 2021 [cited by applicant]
US 20210260201A1 · Chukly et al. · 2021 [cited by applicant]
US 20210275665A1 · Cho · 2021 [cited by applicant]
US 20210277093A1 · Mond et al. · 2021 [cited by applicant]
US 20210388065A1 · Lu et al. · 2021 [cited by applicant]
CN 111088283A · 2020 [cited by applicant]
CN 111285933A · 2020 [cited by applicant]
CN 111303254A · 2020 [cited by applicant]
CN 111303279A · 2020 [cited by applicant]
CN 111303280A · 2020 [cited by applicant]
CN 111333704B · 2020 [cited by applicant]
CN 111333722A · 2020 [cited by applicant]
CN 111420048A · 2020 [cited by applicant]
CN 111423508A · 2020 [cited by applicant]
CN 111440229A · 2020 [cited by applicant]
CN 111471105A · 2020 [cited by applicant]
CN 111499692A · 2020 [cited by applicant]
CN 111499765A · 2020 [cited by applicant]
CN 111518773A · 2020 [cited by applicant]
CN 111560399A · 2020 [cited by applicant]
CN 111574614A · 2020 [cited by applicant]
CN 111592594A · 2020 [cited by applicant]
CN 111592595A · 2020 [cited by applicant]
CN 111607003A · 2020 [cited by applicant]
CN 111620945B · 2020 [cited by applicant]
CN 111620946B · 2020 [cited by applicant]
CN 111647053A · 2020 [cited by applicant]
CN 111647076B · 2020 [cited by applicant]
CN 111647077B · 2020 [cited by applicant]
CN 111662379B · 2020 [cited by applicant]
CN 111690058B · 2020 [cited by applicant]
CN 111690059A · 2020 [cited by applicant]
CN 111690060A · 2020 [cited by applicant]
CN 111714621B · 2020 [cited by applicant]
CN 111718411A · 2020 [cited by applicant]
CN 111732654B · 2020 [cited by applicant]
CN 111732655A · 2020 [cited by applicant]
CN 111732664B · 2020 [cited by applicant]
CN 111748032B · 2020 [cited by applicant]
CN 111778218A · 2020 [cited by applicant]
CN 111793129A · 2020 [cited by applicant]
CN 111825762A · 2020 [cited by applicant]
CN 111825771A · 2020 [cited by applicant]
CN 111848750A · 2020 [cited by applicant]
CN 111848751A · 2020 [cited by applicant]
CN 111848789A · 2020 [cited by applicant]
CN 111875701A · 2020 [cited by applicant]
CN 111909260A · 2020 [cited by applicant]
CN 111909261A · 2020 [cited by applicant]
CN 111909262A · 2020 [cited by applicant]
CN 111909263A · 2020 [cited by applicant]
CN 111925439A · 2020 [cited by applicant]
CN 111925440A · 2020 [cited by applicant]
CN 111925441A · 2020 [cited by applicant]
CN 111925442A · 2020 [cited by applicant]
CN 111925443A · 2020 [cited by applicant]
CN 111925444A · 2020 [cited by applicant]
CN 111944026A · 2020 [cited by applicant]
CN 111978377A · 2020 [cited by applicant]
CN 111978395A · 2020 [cited by applicant]
CN 111978396A · 2020 [cited by applicant]
CN 111978397A · 2020 [cited by applicant]
CN 111978398A · 2020 [cited by applicant]
CN 111978399A · 2020 [cited by applicant]
CN 111995672A · 2020 [cited by applicant]
CN 111995674A · 2020 [cited by applicant]
CN 111995678B · 2020 [cited by applicant]
CN 112010962A · 2020 [cited by applicant]
CN 112010963A · 2020 [cited by applicant]
CN 112010964A · 2020 [cited by applicant]
CN 112010967B · 2020 [cited by applicant]
CN 112062838B · 2020 [cited by applicant]
CN 112062839A · 2020 [cited by applicant]
CN 112062840A · 2020 [cited by applicant]
CN 112062859A · 2020 [cited by applicant]
CN 112076316A · 2020 [cited by applicant]
CN 112094326A · 2020 [cited by applicant]
CN 112094327A · 2020 [cited by applicant]
CN 112094340A · 2020 [cited by applicant]
CN 112094342A · 2020 [cited by applicant]
CN 112094343A · 2020 [cited by applicant]
CN 112125973A · 2020 [cited by applicant]
CN 112159469A · 2021 [cited by applicant]
CN 112175071A · 2021 [cited by applicant]
CN 112175073A · 2021 [cited by applicant]
CN 112194711A · 2021 [cited by applicant]
CN 112210004A · 2021 [cited by applicant]
CN 112250763A · 2021 [cited by applicant]
CN 112251414A · 2021 [cited by applicant]
CN 112300274A · 2021 [cited by applicant]
CN 112341541A · 2021 [cited by applicant]
CN 112341542B · 2021 [cited by applicant]
CN 112390879B · 2021 [cited by applicant]
CN 112409479A · 2021 [cited by applicant]
CN 112409488A · 2021 [cited by applicant]
CN 112430265A · 2021 [cited by applicant]
CN 112442120A · 2021 [cited by applicant]
CN 112485455A · 2021 [cited by applicant]
CN 112500480A · 2021 [cited by applicant]
CN 112500481A · 2021 [cited by applicant]
CN 112513076A · 2021 [cited by applicant]
CN 112521494A · 2021 [cited by applicant]
CN 112521496A · 2021 [cited by applicant]
CN 112522203A · 2021 [cited by applicant]
CN 112538111A · 2021 [cited by applicant]
CN 112552399A · 2021 [cited by applicant]
CN 112574299A · 2021 [cited by applicant]
CN 112574300A · 2021 [cited by applicant]
CN 112625125A · 2021 [cited by applicant]
CN 112625136A · 2021 [cited by applicant]
CN 112626030A · 2021 [cited by applicant]
CN 112626089A · 2021 [cited by applicant]
CN 112646005A · 2021 [cited by applicant]
CN 112661841A · 2021 [cited by applicant]
CN 112724247A · 2021 [cited by applicant]
CN 112724248A · 2021 [cited by applicant]
CN 112794898A · 2021 [cited by applicant]
CN 112794899A · 2021 [cited by applicant]
CN 112851804A · 2021 [cited by applicant]
CN 112980885A · 2021 [cited by applicant]
CN 113045647A · 2021 [cited by applicant]
CN 113072640A · 2021 [cited by applicant]
CN 113150129A · 2021 [cited by applicant]
CN 113150130A · 2021 [cited by applicant]
CN 113150132A · 2021 [cited by applicant]
CN 113150135A · 2021 [cited by applicant]
CN 113151184A · 2021 [cited by applicant]
CN 113173995A · 2021 [cited by applicant]
CN 113185609A · 2021 [cited by applicant]
CN 113214389A · 2021 [cited by applicant]
CN 113215106A · 2021 [cited by applicant]
CN 113234148A · 2021 [cited by applicant]
CN 113234149A · 2021 [cited by applicant]
CN 113234150A · 2021 [cited by applicant]
CN 113234151A · 2021 [cited by applicant]
CN 113248579A · 2021 [cited by applicant]
CN 113248581A · 2021 [cited by applicant]
CN 113264998A · 2021 [cited by applicant]
CN 113292649A · 2021 [cited by applicant]
CN 113292650A · 2021 [cited by applicant]
CN 113307865A · 2021 [cited by applicant]
CN 113336846A · 2021 [cited by applicant]
CN 113354731A · 2021 [cited by applicant]
CN 113354733A · 2021 [cited by applicant]
DE 202020105116 · 2020 [cited by applicant]
EP 3872091A1 · 2021 [cited by applicant]
EP 3885361A1 · 2021 [cited by applicant]
KR 102205028B1 · 2021 [cited by applicant]
KR 102229225B1 · 2021 [cited by applicant]
KR 102233689B1 · 2021 [cited by applicant]
RU 2744274C1 · 2021 [cited by applicant]
WO 2005018535A2 · 2005 [cited by applicant]
WO 2005060520A2 · 2005 [cited by applicant]
WO WO2008068048A2 · 2008 [cited by examiner]
WO 2015179535A1 · 2015 [cited by applicant]
WO 2019147831A1 · 2019 [cited by applicant]
WO 2021001388A1 · 2021 [cited by applicant]
WO 2021026074A1 · 2021 [cited by applicant]
WO 2021035177A2 · 2021 [cited by applicant]
WO 2021045836A1 · 2021 [cited by applicant]
WO 2021058521A1 · 2021 [cited by applicant]
WO 2021072399A1 · 2021 [cited by applicant]
WO 2021096980A1 · 2021 [cited by applicant]
WO 2021148884A1 · 2021 [cited by applicant]
WO 2021151100A1 · 2021 [cited by applicant]
WO 2021155639A1 · 2021 [cited by applicant]
WO 2021163265A1 · 2021 [cited by applicant]
WO 2021168483A2 · 2021 [cited by applicant]
WO 2021173879A1 · 2021 [cited by applicant]
WO 2021180602A1 · 2021 [cited by applicant]
WO 2021183195A1 · 2021 [cited by applicant]
WO 2021183359A1 · 2021 [cited by applicant]
WO 2021183790A1 · 2021 [cited by applicant]
WO 2021190980A1 · 2021 [cited by applicant]
WO 2021203053A1 · 2021 [cited by applicant]
WO 2021222935A2 · 2021 [cited by applicant]
WO 2021226560A1 · 2021 [cited by applicant]
WO 2021233834A1 · 2021 [cited by applicant]
WO 2021239935A1 · 2021 [cited by applicant]
WO 2021242815A1 · 2021 [cited by applicant]
WO 2021245184A1 · 2021 [cited by applicant]
WO 2021249547A1 · 2021 [cited by applicant]
WO 2022090353A1 · 2022 [cited by applicant]
WO 2022162587A1 · 2022 [cited by applicant]
Chen et al., Enhancement and destruction of antibody function by somatic mutation: unequal occurrence is controlled by V gene combinatorial associations. EMBO J. Jun. 15, 1995;14(12):2784-94. (Year: 1995). [cited by examiner]
Edwards et al., The remarkable flexibility of the human antibody repertoire; isolation of over one thousand different antibodies to a single protein, BLyS. J Mol Biol. Nov. 14, 2003;334(1):103-18. (Year: 2003). [cited by examiner]
Koenig et al., Mutational landscape of antibody variable domains reveals a switch modulating the interdomain conformational dynamics and antigen binding. PNAS Jan. 24, 2017 114 (4) E486-E495; first published Jan. 5, 201… [cited by examiner]
Kussie, Paul H., “A Single Engineered Amino Acid Substitution Changes Antibody Fine Specificity”, 1994, Journal of Immunology 152(1): pp. 146-152. (Year: 1994). [cited by examiner]
Andreano et al., “Identification of neutralizing human monoclonal antibodies from Italian Covid-19 convalescent patients,” bioRxiv 2020.05.05.078154; (2020) doi: https://doi.org/10.1101/2020.05.05.078154. [cited by applicant]
Barnes et al., “Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodies,” Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and … [cited by applicant]
Barnes et al., “Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies,” Cell, Volume(182, Issue 4): 828-842, Jun. 23, 2020 (2020). [cited by applicant]
Baum A, Copin R, Ajithdoss D, et al. REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters. bioRxiv 2020:2020.08.02.233320. [cited by applicant]
Baum A, Fulton BO, Wloga E, et al. Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies. Science 2020. [cited by applicant]
Baum et al., “Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies,” Science, vol. (1):1-17, (2020). [Retrieved from the Internet Jun. 30, 2020: <URL: http://sci… [cited by applicant]
Baum et al., “Antibody cocktail to SARS-CoV-2 spike protein prevens rapid mutational escape seen with individual antibodies,” Science, pp. 1-8, (Jun. 15, 2020). [Retrieved from the Internet Jun. 23, 2020 from http://sci… [cited by applicant]
Bertoglio et al., “SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface,” bioRxiv 2020.06.05.135921; (2020) doi: https://doi.org/10.1101/2020.06.05… [cited by applicant]
Blanco-Melo D, Nilsson-Payant BE, Liu WC, et al. Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19. Cell 2020;181:1036-45 e9. [cited by applicant]
Brouwer et al., “Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability” Science 10.1126/Science.abc5902 (2020). [cited by applicant]
Brouwer et al., “Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability” bioRxiv 2020.05.12.088716; doi: https://doi.org/10.1101/2020.05.12.088716. [cited by applicant]
Brouwer et al., “Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability,” bioRxiv 2020.05.12.088716; (2020) doi: https://doi.org/10.1101/2020.05.12.088716. [cited by applicant]
Cao et al., “Potent Neurtalizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Pateitns'B Cells,” Cell, vol. (182): 73-84, (2020). [https://doi.org/10.1016/j.cell.202… [cited by applicant]
Cao et al., “Potent Neutralizing Antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells,” Cell (2020), doi: https://doi.org/10.1016/j.cell.2020.05.025. [cited by applicant]
Case et al., “Neutralizing antibody and soluble ACE2 inhibition of a replication-competent VSV-SARS-CoV-2 and a clinical isolate of SARS-CoV-2,” bioRxiv 2020.05.18.102038; (2020) doi: https://doi.org/10.1101/2020.05.18.… [cited by applicant]
Chen et al., “Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzume 2 receptor,” Cellular & Molecular Immunology (2020) https://doi.org/10.1038/s41423-020-0426-7. [cited by applicant]
Chen et al., “Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies,” Nature Medicine, vol. (27): 717-726, (2021). [https://doi.org/10.1038/s41591-021-01294-w]. [cited by applicant]
Cheng et al., “An insertion unique to SARS-CoV-2 exhibits superantigenic character strengthened by recent mutations,” bioRxiv 2020.05.21.109272; (2020) doi: https://doi.org/10.1101/2020.05.21.109272. [cited by applicant]
Cheng et al., “Impact of South African 501.V2 Variant on SARS-CoV-2 Spike Infectivity and Neutrlization: A Structure-based Computational Assessment,” Bioinformatics, pp. 1-7, (2021). [https://doi.org/10.1101/2021.01.10.… [cited by applicant]
Chi et al., “A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2,” Science 11.1126/science.abc6952 (2020). [cited by applicant]
Chi et al., “A potent neutralizing human antibody reveals the N-terminal domain in the Spike protein of SARS-CoV-2 as a site of vulnerability,” bioRxiv 2020.05.08.083964; (2020) doi: https://doi.org/10.1101/2020.05.08.0… [cited by applicant]
Chi et al., “Humanized Single Domain Antibodies Neutralize SARS-CoV-2 by Targeting Spike Receptor Binding Domain,” bioRxiv 2020.04.14.042010; (2020) doi: https://doi.org/10.1101/2020.04.14.042010. [cited by applicant]
Choi et al., “Characterization of a human monoclonal antibody generated from a B-cell specific for a prefusion-stabilized spike protein of Middle East respiratory syndrome coronavirus,” PLoS ONE 15(5): e0232757. https:/… [cited by applicant]
Choudhury et al., “In silico studies on the comparative characterization of the interactions of SARS-CoV-2 spike glycoprotein with ACE-2 receptor homologs and humans TLRs,” (2020) doi: 10.1002/jmv.25987. [cited by applicant]
Copin et al., “The monoclonal antibody combination REGEN-COV protects against SARS-CoV-2 mutational escape in preclinical and human studies” Cell, vol. (184): 3949-3961, (Jul. 22, 2021). [https://doi.org/10.1016/j.cell.… [cited by applicant]
Coronavirus Disease 2019 (COVID-19) Situation Report—101. 2020. (Accessed Oct. 6, 2020, at https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200430-sitrep-101-covid-19.pdf?sfvrsn=2ba4e093_2.). [cited by applicant]
Crooke et al., “Immunoinformatic identification of B cell and T cell epitopes in the SARS-CoV-2 proteome,” bioRxiv 2020.05.14.093757; (2020) doi: https://doi.org/10.1101/2020.05.14.093757. [cited by applicant]
Custodio et al., “Selection, biophysical and structural analysis of synthetic nanobodies that effectively neutralize SARS-CoV-2,” bioRxiv 2020.06.23.165415; (2020) doi: https://doi.org/10.1101/2020.06.23.165415. [cited by applicant]
Davidson et al., “Mechanism of Binding to Ebola Virus Glycoprotein by the ZMapp, ZMAb, and MB-003 Cocktail Antibodies,” Journal of Virology, vol. (89.21): 10982-10992, (2015). [cited by applicant]
Dinnon, III et al., “A mouse-adapter SARS-CoV-2 model for the evaluation of COVID-19 medical countermeasures,” bioRxiv 2020.05.06.081497; (2020) doi: https://doi.org/10.1101/2020.05.06.081497. [cited by applicant]
Dong et al., “Development of multi-specific humanized llama antibodies blocking SARS-CoV-2/ACE2 interaction with high affinity and avidity,” Emerging Microbes & Infections, 9:1, 1034-1036, DOI: 10.1080/22221751.2020.176… [cited by applicant]
Ejemel et al., “IgA Mab blocks SARS-CoV-2 Spike-ACE2 interaction providing mucosal immunity,” bioRxiv 2020.05.15.096719; doi: https://doi.org/10.1101/2020.05.15.096719. [cited by applicant]
Galson et al., “Deep sequencing of B cell receptor repertoires from COVID-19 patients reveal strong convergent immune signature,” bioRxiv 2020.05.20.106294; doi: https://doi.org/10.1101/2020.05.20.106294. [cited by applicant]
Garde et al., “In the race to develop a coronavirus treatment, Regeneron thinks it has the inside track,” STAT, pp. 1-7, Feb. 5, 2020 (2020). [https://www.statnews.com/2020/02/05/in-the-race-to-develop-a-coronavirus-tre… [cited by applicant]
Giron et al., “On the Interactions of the receptor-binging domain of SARS-CoV-1 and SARS-CoV-2 spike proteins with monoclonal antibodies and the receptor ACE2,” Virus Research 285 (2020) 198021. [cited by applicant]
Goncalves et al., “SARS-CoV-2 mutations and where to find them: An in silico perspective of structural changes and antigenicity of the Spike protein,” bioRxiv 2020.05.21.108563; (2020) doi: https://doi.org/10.1101/2020.… [cited by applicant]
Goyal P, Choi JJ, Pinheiro LC, et al. Clinical Characteristics of Covid-19 in New York City. N Engl J Med 2020. [cited by applicant]
Grifoni et al., “Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals,” Cell (2020), doi: https://doi.org/10.1016/j.cell.2020.05.015. [cited by applicant]
Group RC, Horby P, Lim WS, et al. Dexamethasone in Hospitalized Patients with Covid-19—Preliminary Report. N Engl J Med 2020. [cited by applicant]
Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med 2020;382:1708-20. [cited by applicant]
Gudbjartsson DF, Helgason A, Jonsson H, et al. Spread of SARS-CoV-2 in the Icelandic Population. N Engl J Med 2020;382:2302-15. [cited by applicant]
Hanke et al., “An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor interaction,” bioRxiv 2020.06.02.130161; (2020) doi: https://doi.org/10.1101/2020.06.02.130161. [cited by applicant]
Hansen et al., “Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail,” Science, vol. (1):1-47, (2020). [Retrieved from the Internet Jun. 30, 2020: <URL: http://science.sciencemag.org]. [cited by applicant]
Hansen et al., “Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail,” Science, 1-10, (2020). [Retrieved from the Internet Jul. 29, 2020: <http://science.sciencemag.org>]. [cited by applicant]
Hansen et al., “Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail,” Science, pp. 1-10, (Jun. 15, 2020). [Retrieved from the Internet Jun. 23, 2020 from http://science.sciencemag.org/… [cited by applicant]
Hansen et al., supplementary materials for “Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail,” Science, pp. 1-30, (Jun. 15, 2020). [science.scieocemag.org/cgi/conrent/fu1Vscience.ab… [cited by applicant]
Hansen J, Baum A, Pascal KE, et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science 2020. [cited by applicant]
Heurich et al., “TMPRSS2 and ADAM17 Cleave ACE2 Differentially and Only Proteolysis by TMPRSS2 Augments Entry Driven by the Severe Acute Respiratory Syndrome Coronavirus Spike Protein,” Journal of Virology, vol. 88, No.… [cited by applicant]
Hsieh et al., “Structure-based design of prefusion-stabilized SARS-CoV-2 Spikes,” bioRxiv 2020.05.30.125484; (2020) doi: https://doi.org/10.1101/2020.05.30.125484. [cited by applicant]
Huibin et al., “Cross-reactive Antibody Response between SARS-CoV-2 and SARS-CoV Infections,” Cell Reports 31, 107725; Jun. 2, 2020. https://doi.org/10.1016/j.celrep.2020.107725. [cited by applicant]
Hulburt et al., “Structural basis for potent neurtralization of SARS-CoV-2 and role of antibody affinity maturation,” bioRxiv 2020.06.12.148692; doi: https://doi.org/10.1101/2020.06.12.148692. [cited by applicant]
Huo et al., “Neutralization of SARS-CoV-2 by destruction of the prefusion Spike,” bioRxiv 2020.05.05.079202; (2020) doi: https://doi.org/10.1101/2020.05.05.079202. [cited by applicant]
Interim Clinical Guidance for Management of Patients with Confirmed Coronavirus Disease (COVID- 19)—Clinical Care Guidance—Updated Sep. 10, 2020. 2020. (Accessed Oct. 6, 2020). [cited by applicant]
Jacobs et al., “Neutralizing antibodies mediate virus-immune pathology of COVID-19,” Science Direct, Medical Hypotheses 143; 109884, pp. 1-4. (2020). [cited by applicant]
Joyner MJ, Senefeld JW, Klassen SA, et al. Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience. medRxiv 2020:2020.08.12.20169359. [cited by applicant]
Ju et al., “Human neutralizing antibodies elicited by SARS-CoV-2 infection,” Nature https://doi.org/10.1038/s41586-020-2380-z (2020). [cited by applicant]
Ju et al., “Potent human neutralizing antibodies elicited by SARS-CoV-2 infection,” bioRxiv 2020.03.21.990770; (2020) doi: https://doi.org/10.1101/2020.03.21.990770. [cited by applicant]
Keeffe et al., “A Combination of Two Human Monoclonal Antibodies Prevents Zika Virus Escape Mutations in Non-human Primates,” Cell Reports, vol. (25): 1385-1394, (2018). [https://doi.org/10.1016/j.celrep.2018.10.031]. [cited by applicant]
Kreer et al., “Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients,” bioRxiv 2020.06.12.146290; doi: https://doi.org/10.1101/2020.06.12.146290. [cited by applicant]
Kugelman et al., “Emergence of Ebola Virus Escape Variants in Infected Nonhuman Primates Treated with the MB-003 Antibody Cocktail,” Cell Reports, vol. (12): 2111-2120, (2015). [http://dx.doi.org/10.1016/j.celrep.2015.0… [cited by applicant]
Lan et al., “Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor,” Nature, vol. 581, May 14, 2020. [cited by applicant]
Larsen et al., “Afucosylated immunoglobulin G resposnes are a hallmark of enveloped virus infections and show an exacerbated phenotype in COVID-19,” bioRxiv 2020.05.18.099507; doi: https://doi.org/10.1101/2020.05.18.099… [cited by applicant]
Lavezzo E, Franchin E, Ciavarella C, et al. Suppression of a SARS-CoV-2 outbreak in the Italian municipality of Vo'. Nature 2020;584:425-9. [cited by applicant]
Lee et al., “CD-8+ T cell cross-reactivity against SARS-CoV-2 conferred by toerh coronavirus strains and influenza virus,” bioRxiv 2020.05.20.107292; doi: https://doi.org/10.1101/2020.05.20.107292. [cited by applicant]
Lee S, Kim T, Lee E, et al. Clinical Course and Molecular Viral Shedding Among Asymptomatic and Symptomatic Patients With SARS-CoV-2 Infection in a Community Treatment Center in the Republic of Korea. JAMA Intern Med 20… [cited by applicant]
Li et al., “Potent neutralization of SARS-CoV-2 in vitro and in an animal model by a human monoclonal antibody,” bioRxiv 2020.05.13.093088; doi: https://doi.org/10.1101/2020.05.13.093088. [cited by applicant]
Li et al., “Potent synthetic nanobodies against SARS-CoV-2 and molecular basis for neutralization,” bioRxiv 2020.06.09.143438; doi: https://doi.org/10.1101/2020.06.09.143438. [cited by applicant]
Li et al., “Repurposing host-based therapeutics to control coronavirus and influenza virus,” Drug Discovery Today, vol. 24 (No. 3): 726-736, (Mar. 2019). [https://doi.org/10.1016/j.drudis.2019.01.018]. [cited by applicant]
Li L, Zhang W, Hu Y, et al. Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial. JAMA 2020;324:460-70. [cited by applicant]
Lotfi et al., “covid-19: Transmission, prevention, and potential therapeutic opportunities,” Science Direct, Clinica Chimica Acta (508): 254-266, (2020). [cited by applicant]
Lou et al., “Cross-neutralization antibodies against SARS-cOv-2 and RBD mutations from convalescent patient antibody libraries,” bioRxiv 2020.06.06.137513; doi: https://doi.org/10.1101/2020.06.06.137513. [cited by applicant]
Lui et al., “Trimeric SARS-CoV-2 Spike interacts with dimeric ACE2 with limited intra-Spike avidity,” bioRxiv 2020.05.21.109157; doi: https://doi.org/10.1101/2020.05.21.109157. [cited by applicant]
Lv et al., “Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody,” bioRxiv 2020.06.02.129098; doi: https://doi.org/10.1101/2020.06.02.129098. [cited by applicant]
Magleby R, Westblade LF, Trzebucki A, et al. Impact of SARS-CoV-2 Viral Load on Risk of Intubation and Mortality Among Hospitalized Patients with Coronavirus Disease 2019. Clin Infect Dis 2020. [cited by applicant]
Matsuyama et al., “Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells,” PNAS, vol. 117 (No. 13), pp. 7001-7003, (Mar. 31, 2020). [<www.pnas.org/cgi/doi/10.1073/pnas.2002589117>]. [cited by applicant]
Meirson et al., “Structural basis of SARS-CoV-2 spike protein induced by ACE2,” bioRxiv 2020.05.24.113175; doi: https://doi.org/10.1101/2020.05.24.113175. [cited by applicant]
Meulen et al., “Human Monoclonal Antibody Combination against SARS Coronavirus: Synergy and Coverage of Escape Mutants,” PLoS Medicine, vol. (3.7): 1071-1079, (2006). [www.plosmedicine.org]. [cited by applicant]
Miersch et al., “Synthetic Antibodies neutralized SARS-CoV-2 infection of mammalian cells,” bioRxiv 2020.06.05.137349; doi: https://doi.org/10.1101/2020.06.05.137349. [cited by applicant]
Mossel et al., “Exogenous ACE2 Expression Allows Refractory Cell Lines to Support Severe Acute Respiratory Syndrome Coronavirus Replication,” Journal of Virology, vol. 79, No. 6; Mar. 2005; pp. 3846-3850. [cited by applicant]
Nascimento Jr. et al., “SARS, MERS and SARS-CoV-2 (COVI19) treatment: a patent review,” Expert Opinion on Therapeutic Patents, DOI: 10.1080/13543776.2020.1772231. [cited by applicant]
Ng et al., “Pre-existing and de novo humoral immunmity to SARS-CoV-2 in humans,” bioRxiv 2020.05.14.095414; doi: https://doi.org/10.1101/2020.05.14.095414. [cited by applicant]
Ni et al., “Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals,” Immunity 52, 1-7; Jun. 16, 2020. [cited by applicant]
Nieto et al., “Fast isolation of sub-nanomolar affinity alpaca nanobody against the Spike RBD of SARSCoV-2 by combining bacterial display and a simple single-step density gradient selection,” bioRxiv, vol. (1):1-27, (20… [cited by applicant]
Noy-Porat et al., “Tiger team: a panel of human beutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes,” bioRxiv 2020.05.20.106609; doi: https://doi.org/10.1101/2020.05.20.106609. [cited by applicant]
Okba et al., “Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease 2019 Patients,” Research vol. 26, No. 7; Apr. 8, 2020. [cited by applicant]
Oran DP, Topol EJ. Prevalence of Asymptomatic SARS-CoV-2 Infection : A Narrative Review. Ann Intern Med 2020;173:362-7. [cited by applicant]
Park et al., “Spike protein binding prediction with neutralizing antibodies of SARS-CoV-2”, bioRxiv 2020.02.22.951178; (2020) doi: https://doi.org/10.1101/2020.02.22.951178. [cited by applicant]
Pascal et al., “Development of Clinical-Stage Human Monoclonal Antibodies That Treat Advanced Ebola Virus Disease in Nonhuman Primates,” The Journal of Infectious Diseases, vol. (218): S612-S626, (2018). [cited by applicant]
Pascal et al., “Pre-and postexposure efficacy of fully human antibodies against Spike protein in a novel humanized mouse model of MERS-CoV infection,” PNAS, vol. (112 No. 28): 8738-8743, (2015). [www.pnas.org/cgi/doi/10… [cited by applicant]
Pinto et al., “Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody,” Nature https://doi.org/10.1038/s41586-020-2349-y (2020). [cited by applicant]
Pinto et al., “Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody,” Nature, vol. (583): 290-308, (2020). [https://doi.org/10.1038/s41586-020-2 349-y]. [cited by applicant]
Poh et al., “Two linear epitopes on the SARS-CoV-2 spike protein that elicit neutralising antibodies in COVID-19 patients,” Nature Communications (2020)11:2806. https://doi.org/10.1038s41467-020-16638-2. [cited by applicant]
Qiang et al., “Monoclonal Antibodies Capable of Binding SARS-CoV-2 Spike Protein Receptor Binding Motif Specifically Prevent GM-CSF Induction,” bioRxiv, pp. 1-27, Sep. 4, 2020 (2020). [cited by applicant]
Ravichandran et al., “Antibody repertoire induced by SARS-CoV-2 spike protein immunogens,” bioRxiv 2020.05.12.091918; doi: https://doi.org/10.1101/2020.05.12.091918. [cited by applicant]
Raybould et al., “CoV-AbDab: the Coronavirus Antibody Database,” bioRxiv 2020.05.15.077313; doi: https://doi.org/10.1101/2020.05.15.077313. [cited by applicant]
Regeneron. Regeneron and Sanofi Provide Update on Kevzara (Sarilumab) Phase 3 U.S. Trial in COVID-19 Patients. 2020. [cited by applicant]
Reichert, “Coronavirus in the crosshairs, Part 1—The Antibody Society,” pp. 1-7, (2020). [https://www.antibodysociety.org/coronavirus/coronavirus-in-the-crosshairs/]. [cited by applicant]
Reichert, “Coronavirus in the crosshairs, Part 4: Antibody therapeutics—The Antibody Society,” pp. 1-10, (2020). [https://www.antibodysociety.org/covid-19/coronavirus-in-the-crosshairs-part-4-antibody-therapeutics/]. [cited by applicant]
Richardson S, Hirsch JS, Narasimhan M, et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA 2020. [cited by applicant]
Robbiani et al., “Convergent antibody responses to SARS-CoV-2 in convalescent individuals,” Nature https://doi.org/10.1038/s41586-020-2456-9 (2020). [cited by applicant]
Robbiani et al., “Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals,” bioRxiv 2020.05.13.092619; (2020) doi: https://doi.org/10.1101/2020.05.13.092619. [cited by applicant]
Roche. Roche Provides an Update on the Phase III COVACTA Trial of ACTEMRA/ROACTEMRA in Hospitalized Patients with Severe COVID-19 Associated Pneumonia. 2020. [cited by applicant]
Rockx et al., “Escape from Human Monoclonal Antibody Neutralization Affects in Vitro and In Vivo Fitness of Severe Acute Respiratory Syndrome Coronavirus,” The Journal of Infectious Diseases, vol. (201): 946-955, (2010)… [cited by applicant]
Rogers et al., “Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model,” Science 10.1126/scienec.abc7520 (2020). [cited by applicant]
Rogers et al., “Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model,” bioRxiv 2020.05.11.088674; doi: https://doi.org/10.1101/2020.05.11.088674. [cited by applicant]
Rosas I, Bräu N, Waters M, et al. Tocilizumab in Hospitalized Patients With COVID-19 Pneumonia. medRxiv 2020:2020.08.27.20183442. [cited by applicant]
Rouet et al., “Potent SARS-CoV-2 binding and neutralization through maturation of iconic SARS-CoV-1 antibodies,” bioRxiv, pp. 1-52, (2020). [https://doi.org/10.1101/2020.12.14.422791]. [cited by applicant]
Seydoux et al., “Analysis of a SARS-CoV-2 infected individual reveals development of potent neutralizing antibodies to distinct epitopes with limited somatic mutation ,” Immunity 4384; https://doi.org/10.1016/j.immuni.2… [cited by applicant]
Seydoux et al., “Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual,” bioRxiv 2020.05.12.091298; doi: https://doi.org/10.1101/2020.05.12.091298. [cited by applicant]
Shen et al., “TMPRSS2: A potential target for treatment of influenza virus and coronavirus infections,” Biochimie at ScienceDirect, vol. 142: 1-10, (2017). [http://dx.doi.org/10.1016/j.biochi.2017.07.016]. [cited by applicant]
Shi et al., “A Human neutralizing antibody targets the receptor binding cite of SARS-CoV-2,” Nature https://doi.org/10.1038/s41586-020-2381-y (2020). [cited by applicant]
Simoes EAF, Forleo-Neto E, Geba GP, et al. Suptavumab for the Prevention of Medically Attended Respiratory Syncytial Virus Infection in Preterm Infants. Clin Infect Dis 2020. [cited by applicant]
Stave et al., “Antibody and Antigen Contact Residues Define Epitope and Paratope Size and Structure,” The Journal of Immunology, vol. (191): 1428-1435, (2013). [www.jimmunol.org/cgi/doi/10.4049/jimmunol.1203198]. [cited by applicant]
Supasa et al., “Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera,” Cell, vol. (184): 2201-2211, (2021). Https://doi.org/10.1016/j.cell.2021.02.033]. [cited by applicant]
Suthar et al., “Rapid generation of neutralizing antibody responses in COVID-19 patients,” Cell Reports Medicine, 1-36 pages (2020). [https://doi.org/10.1016/j.xcrm.2020.100040]. [cited by applicant]
Tai et al., “Identification of SARS-CoV RBD-targeting monoclonal antibodies with crossreactive or neutralizing activity against SARS-CoV-2,” Antiviral Research, Science Direct, vol. (179):1-6, (2020). [www.elsevier.com/… [cited by applicant]
Tenforde MW, Kim SS, Christopher J. Lindsell, et al. Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID-19 in a Multistate Health Care Systems Network—United States, Mar.-J… [cited by applicant]
Teng et al., “Systemic Effects of Missense Mutations on SARS-CoV-2 Spike Glycoprotein Stability and Receptor Binding Affinity,” bioRxiv, vol. (1):1-36, (2020). [https://doi.org/10.1101/2020.05.21.109835]. [cited by applicant]
Tian et al., “Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody,” Emerging Microbes & Infections, vol. (17): 647-649, Feb. 17, 2020 (2020). [cited by applicant]
U.S. Appl. No. 16/912,678, Notice of Allowance mailed Jul. 29, 2020. [cited by applicant]
U.S. Appl. No. 16/996,297, Non-Final Office Action mailed Dec. 8, 2020. [cited by applicant]
U.S. Appl. No. 16/996,297, Notice of Allowance mailed Jan. 25, 2021. [cited by applicant]
U.S. Appl. No. 17/021,286, Non-Final Office Action mailed Dec. 23, 2020. [cited by applicant]
U.S. Appl. No. 17/021,286, Notice of Allowance mailed Jan. 22, 2021. [cited by applicant]
Vandergaast et al., “Development and validation of IMMUNO-COVTM: a high-throughput clinical assay for detecting antibodies that neutralize SARS-CoV-2,” bioRxiv, pp. 1-32, (2020). [https://doi.org/10.1101/2020.05.26.1175… [cited by applicant]
Walker et al., “Passive immunotherapy of viral infections: ‘super-antibodies’ enter the fray,” Nature Reviews at Immunology, vol. 18: 297-308, (2018). [doi:10.1038/nri.2017.148]. [cited by applicant]
Wan et al., “Human IgG cell neutralizing monoclonal antibodies block SARS-CoV-2 infect,” bioRxiv, vol. (1):1-25, (2020). [https://doi.org/10.1101/2020.05.19.104117]. [cited by applicant]
Wan et al., “Human IgG cell neutralizing monoclonal antibodies block SARS-CoV-2 infection,” bioRxiv, pp. 1-28, (May 21, 2020). [doi:https://doi.org/10.1101/2020.05.19.104117]. [cited by applicant]
Wang et al., “A human monoclonal antibody blocking SARS-CoV-2 infection,” Supplemental information, 1-13 pages (2020). [cited by applicant]
Wang et al., “A human monoclonal antibody blocking SARS-CoV-2 infection,” Nature Communications, 1-7, (2020). [https://doi.org/10.1038/s41467-020-16256-y | www.nature.com/naturecommunications]. [cited by applicant]
Wang et al., “A human monoclonal antibody blocking SARS-CoV-2 infection,” bioRxiv, pp. 1-24, (Mar. 12, 2020). [doi:https://doi.org/10.1101/2020.03.11.987958]. [cited by applicant]
Wang et al., “E484K mutation in SARS-CoV-2 Rbd enhances binding affinity with hACE2 but reduces interactions with neutralizing antibodies and nanobodies: Binding free energy calculation studies,” bioRxiv, pp. 1-18, (202… [cited by applicant]
Wang et al., “Importance of Neutralizing Monoclonal Antibodies Targeting Multiple Antigenic Sites on the Middle East Respiratory Syndrome Coronavirus Spike Glycoproein To Avoid Neutralization Escape,” Vaccines and Antiv… [cited by applicant]
Wang et al., “SARS-CoV-2 Neutralizing Antibody Responses Are More Robust in Patients with Severe Disease,” bioRxiv, vol. (1): 1-9, (2020). [https://doi.org/10.1101/2020.06.13.150250]. [cited by applicant]
Wang et al., “Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2,” Cell, vol. (181):894-904, (2020). [https://doi.org/10.1016/j.cell.2020.03.045]. [cited by applicant]
Watanabe et al., “Site-specific glycan analysis of the SARS-CoV-2 spike,” Science, vol. (1): 1-9, (2020). [Retrieved from the Internet May 13, 2020: <URL: http://science.sciencemag.org>; Y. Watanabe et al., Science 10.1… [cited by applicant]
Watanabe et al., “Vulnerabilities in coronavirus glycan shields despite extensive glycosylation,” Nature Communications, vol. (11):1-10, (2020). [https://doi.org/10.1038/s41467-020-16567-0]. [cited by applicant]
Wec et al., “Broad neutralization of SARS-related viruses by human monoclonal antibodies,” Science, vol. (1):1-12, (2020). [Retrieved from the Internet Jun. 17, 2020: <URL: http://science.sciencemag.org>; A. Z. Wec et a… [cited by applicant]
Wec et al., “Broad neutralization of SARS-related viruses by human monoclonal antibodies,” Science, vol. (1):1-30, (2020). [science.sciencemag.org/cgi/content/full/science.abc7424/DC1>]. [cited by applicant]
Wec et al., “Broad sarbecovirus neutralizing antibodies define a key site of vulnerability on the SARS-CoV-2 spike protein,” bioRxiv, 1-18, (2020). [https://doi.org/10.1101/2020.05.15.096511]. [cited by applicant]
WHO Director-General's Opening Remarks at the Media Briefing on COVID-19—Mar. 11, 2020. 2020. (Accessed Jun. 9, 2020, at https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefin… [cited by applicant]
WIPO Application No. PCT/US2020/039707, PCT International Search Report and Written Opinion of the International Searching Authority mailed Nov. 9, 2020. [cited by applicant]
WIPO Application No. PCT/US2020/039707, PCT Third Party Observation Communication mailed May 2, 2022. [cited by applicant]
WIPO Application No. PCT/US2021/034187, PCT International Search Report and Written Opinion of the International Searching Authority mailed Nov. 2, 2021. [cited by applicant]
WIPO Application No. PCT/US2021/035556, PCT International Search Report and Written Opinion of the International Searching Authority mailed Sep. 10, 2021. [cited by applicant]
WIPO Application No. PCT/US2022/018918, PCT International Search Report and Written Opinion of the International Searching Authority mailed Jun. 17, 2022. [cited by applicant]
Wolfel R, Corman VM, Guggemos W, et al. Virological assessment of hospitalized patients with COVID-2019. Nature 2020;581:465-9. [cited by applicant]
Wrapp et al., “Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation,” Science, vol. (367):1260-1263, (2020). [Retrieved from the Internet Jul. 29, 2020: <http://science.sciencemag.org>]. [cited by applicant]
Wrapp et al., “Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies,” Cell, vol. (181):1-12, (2020). [https://doi.org/10.1016/j.cell.2020.04.031]. [cited by applicant]
Wu et al., “A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2,” Science, 1-8, (2020). [Retrieved from the Internet May 14, 2020: <URL: http://science.sciencemag.org>;… [cited by applicant]
Wu et al., “Fully human single-domain antibodies against SARS-CoV-2,” bioRxiv 2020.03.30.015990; (2020) doi: https://doi.org/10.1101/2020.03.30.015990. [cited by applicant]
Wu et al., “Identification of Human Single-Domain Antibodies against SARS-CoV-2,” Cell Host & Microbe, vol. (27): 1-8, (2020). [https://doi.org/10.1016/j.chom.2020.04.023]. [cited by applicant]
Wu et al., “Identification of Human Single-Domain Antibodies against SARS-CoV-2,” Cell Host & Microbe, vol. (27):S 891-898, (2020). [cited by applicant]
Yi et al., “Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies,” Cellular & Molecular Immunology, 1-10, (2020). [cited by applicant]
Yi et al., “Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies,” Cellular & Molecular Immunology, vol. (17): 621-630, (2020). [www.nature.co… [cited by applicant]
Yu et al., “DNA vaccine protection against SARS-CoV-2 in rhesus macaques,” Science, 1-11, (2020). [Retrieved from the Internet May 22, 2020: <URL: http://science.sciencemag.org>; J. Yu et al., [cited by applicant]
Yuan et al., “A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV,” Science, vol. (368):630-633, (2020). [Retrieved from the Internet May 20, 2020: <URL: http://science.sciencem… [cited by applicant]
Yuan et al., “Isolation of and Characterization of Neutralizing Antibodies to Covid-19 from a Large Human Naïve scFv Phage Display Library,” bioRxiv, 1-15, (2020). [https://doi.org/10.1101/2020.05.19.104281]. [cited by applicant]
Yuan et al., “Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants,” bioRxiv, pp. 1-50, (2021). [https://doi.org/10.1101.2021.02.16.430500]. [cited by applicant]
Zhang et al., “Immunization with the receptor-binding domain of SARS-CoV-2 elicits antibodies cross-neutralizing SARS-CoV-2 and SARS-CoV without antibody-dependent enhancement,” bioRxiv, 1-33, (2020). [https://doi.org/1… [cited by applicant]
Zhang et al., “The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China,” Clinical Immunology at ScienceDirect,… [cited by applicant]
Zheng et al., “Isolation of a human monoclonal antibody specific for the receptor binding domain of SARS-CoV-2 using a competitive phage biopanning strategy,” Antibody Therapeutics, vol. (3.2):95-100, (2020). [Retrieved… [cited by applicant]
Zheng et al., “Novel antibody epitopes dominate the antigenicity of spike glycoprotein in SARS-CoV-2 compared to SARS-CoV,” Cellular & Molecular Immunology, vol. (17):536-538, (2020). [https://doi.org/10.1038/s41423-020… [cited by applicant]
Zhou et al., “A pneumonia outbreak associated with a new coronavirus of probable bat origin,” Nature, vol. (579): 270-289, (2020). [https://doi.org/10.1038/s41586-020-2012-7]. [cited by applicant]
Zhou et al., “Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera,” Cell, vol. (189): 2348-2361, (2021). [https://doi.org/10.1016/j.cell.2021.02.037]. [cited by applicant]
Zhu et al., “Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial,” the lancet, vol. (395): 1845-1854… [cited by applicant]
Zost et al., “Potently neutralizing human antibodies that block SARS-CoV-2 receptor binding and protect animals,” bioRxiv, 1-35, (2020). [https://doi.org/10.1101/2020.05.22.111005]. [cited by applicant]
Zost et al., “Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein,” bioRxiv, 1-48, (2020). [https://doi.org/10.1101/2020.05.12.091462]. [cited by applicant]
U.S. Appl. No. 63/004,312, filed Apr. 2, 2020. [cited by applicant]
U.S. Appl. No. 63/014,687, filed Apr. 23, 2020. [cited by applicant]
U.S. Appl. No. 63/025,949, filed May 15, 2020. [cited by applicant]
U.S. Appl. No. 63/030,260, filed May 26, 2020. [cited by applicant]
U.S. Appl. No. 63/033,198, filed Jun. 1, 2020. [cited by applicant]
U.S. Appl. No. 63/034,348, filed Jun. 3, 2020. [cited by applicant]
U.S. Appl. No. 63/034,865, filed Jun. 4, 2020. [cited by applicant]
U.S. Appl. No. 63/036,956, filed Jun. 9, 2020. [cited by applicant]
U.S. Appl. No. 63/038,274, filed Jun. 12, 2020. [cited by applicant]
U.S. Appl. No. 63/043,336, filed Jun. 24, 2020. [cited by applicant]
U.S. Appl. No. 16/912,678, filed Jun. 25, 2020, now U.S. Pat. No. 10,787,501. [cited by applicant]
PCT/US2020/039707, Jun. 25, 2020, WO 2021/045836. [cited by applicant]
U.S. Appl. No. 63/060,592, filed Aug. 3, 2020. [cited by applicant]
U.S. Appl. No. 63/062,961, filed Aug. 7, 2020. [cited by applicant]
U.S. Appl. No. 63/065,799, filed Aug. 14, 2020. [cited by applicant]
U.S. Appl. No. 16/996,297, filed Aug. 18, 2020, now U.S. Pat. No. 10,975,139. [cited by applicant]
U.S. Appl. No. 17/021,286, filed Sep. 15, 2020, now U.S. Pat. No. 10,954,289. [cited by applicant]
U.S. Appl. No. 63/084,881, filed Sep. 29, 2020. [cited by applicant]
U.S. Appl. No. 63/085,066, filed Sep. 29, 2020. [cited by applicant]
U.S. Appl. No. 63/089,399, filed Oct. 8, 2020. [cited by applicant]
U.S. Appl. No. 63/090,690, filed Oct. 12, 2020. [cited by applicant]
U.S. Appl. No. 63/094,133, filed Oct. 20, 2020. [cited by applicant]
U.S. Appl. No. 63/093,888, filed Oct. 20, 2020. [cited by applicant]
U.S. Appl. No. 63/105,779, filed Oct. 26, 2020. [cited by applicant]
U.S. Appl. No. 63/106,696, filed Oct. 28, 2020. [cited by applicant]
U.S. Appl. No. 63/112,140, filed Nov. 10, 2020. [cited by applicant]
U.S. Appl. No. 63/112,143, filed Nov. 10, 2020. [cited by applicant]